Adult height after GH therapy in 188 Ullrich-Turner syndrome patients: results of the German IGLU Follow-up Study 2001

Paediatric Endocrinology Section, University Children's Hospital, Tubingen, Germany. mlranke@med.uni-tuebingen.de

OBJECTIVES: We aimed to evaluate the factors influencing true adult height (HT) after long-term (from 1987 to 2000) GH treatment in Ullrich-Turner syndrome (UTS) based on modalities conceived in the 1980s. DESIGN: Out of 347 near-adult (>16 Years) patients from 96 German centres, whose longitudinal growth was documented within KIGS (Pharmacia International Growth Database), 188 (45, X=59%; bone age >15 Years) were available for further anthropometric measurements. RESULTS: At a median GH dose of 0.88 (10th/90th percentiles: 0.47/1.06) IU/kg per week, a gain of 6.0 (-1.3/+13) cm above the projected adult height was recorded. Variables were recorded at GH start, after 1 Year GH, puberty onset, and last visit on GH therapy. At these visits, the median ages were 11.7, 12.7, 14.2, 16.6 and 18.7 Years; and median heights, 0.4, 1.1, 1.7, 1.7 and 1.3 SDS (UTS) respectively. Height gain (DeltaHT) after GH discontinuation was 1.5 cm. Total DeltaHT correlated (P<0.001) negatively with bone age and HT SDS at GH start, but positively with DeltaHT after the first Year, DeltaHT at puberty onset, and GH duration. Final HT correlated (P<0.001) positively with HT at GH start, first-Year DeltaHT, and HT at puberty onset. Body mass index increased slightly (P<0.05), with values at start and adult follow-up correlating highly (R=0.70, P<0.001). No major side effects of GH occurred. CONCLUSIONS: GH dosages conceived in the 1980s are safe but too low for most UTS patients. HT gain and height are determined by age and HT at GH start. Height gain during the first Year on GH is indicative of overall height gain. After spontaneous or induced puberty, little gain in height occurs.

This article has been cited by other articles:

				M. L. Davenport, B. J. Crowe, S. H. Travers, K. Rubin, J. L. Ross, P. Y. Fechner, D. F. Gunther, C. Liu, M. E. Geffner, K. Thrailkill, et al. Growth Hormone Treatment of Early Growth Failure in Toddlers with Turner Syndrome: A Randomized, Controlled, Multicenter Trial J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3406 - 3416. [Abstract] [Full Text] [PDF]

				C. E. Hamelin, G. Anglin, C. A. Quigley, C. L. Deal, and on behalf of the Canadian Growth Hormone Advisory Genomic Imprinting in Turner Syndrome: Effects on Response to Growth Hormone and on Risk of Sensorineural Hearing Loss J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 3002 - 3010. [Abstract] [Full Text] [PDF]

				M D C Donaldson, E J Gault, K W Tan, and D B Dunger Optimising management in Turner syndrome: from infancy to adult transfer Arch. Dis. Child., June 1, 2006; 91(6): 513 - 520. [Abstract] [Full Text] [PDF]

				P Cabanas, T Garcia-Caballero, J Barreiro, L Castro-Feijoo, R Gallego, T Arevalo, R Canete, and M Pombo Papillary thyroid carcinoma after recombinant GH therapy for Turner syndrome Eur. J. Endocrinol., October 1, 2005; 153(4): 499 - 502. [Abstract] [Full Text] [PDF]

				L. Soriano-Guillen, J. Coste, E. Ecosse, J. Leger, M. Tauber, S. Cabrol, M. Nicolino, R. Brauner, the StaTur Study Group, J.-L. Chaussain, et al. Adult Height and Pubertal Growth in Turner Syndrome after Treatment with Recombinant Growth Hormone J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5197 - 5204. [Abstract] [Full Text] [PDF]

				The Canadian Growth Hormone Advisory Committee Impact of Growth Hormone Supplementation on Adult Height in Turner Syndrome: Results of the Canadian Randomized Controlled Trial J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3360 - 3366. [Abstract] [Full Text] [PDF]

				H. G. Doerr, M. Bettendorf, B. P. Hauffa, O. Mehls, C.-J. Partsch, E. Said, S. Sander, H.-P. Schwarz, N. Stahnke, H. Steinkamp, et al. Uterine size in women with Turner syndrome after induction of puberty with estrogens and long-term growth hormone therapy: results of the German IGLU Follow-up Study 2001 Hum. Reprod., May 1, 2005; 20(5): 1418 - 1421. [Abstract] [Full Text] [PDF]

				V. P. Sybert and E. McCauley Turner's Syndrome N. Engl. J. Med., September 16, 2004; 351(12): 1227 - 1238. [Full Text] [PDF]

				M. B. Ranke, A. Lindberg, D. D. Martin, B. Bakker, P. Wilton, K. Albertsson-Wikland, C. T. Cowell, D. A. Price, and E. O. Reiter The Mathematical Model for Total Pubertal Growth in Idiopathic Growth Hormone (GH) Deficiency Suggests a Moderate Role of GH Dose J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4748 - 4753. [Abstract] [Full Text] [PDF]